Видео ютуба по тегу Bpdcn

Monitoring for and managing CLS in patients with BPDCN treated with tagraxofusp-based regimens
Monitoring for and managing CLS in patients with BPDCN treated with tagraxofusp-based regimens
Approaching treatment decisions in newly diagnosed BPDCN
Approaching treatment decisions in newly diagnosed BPDCN
TAG-AZA-VEN triplet therapy in patients with BPDCN: results of a Phase II trial
TAG-AZA-VEN triplet therapy in patients with BPDCN: results of a Phase II trial
Triplet Therapy for BPDCN: Tagraxofusp + Azacitidine + Venetoclax — What You Need to Know
Triplet Therapy for BPDCN: Tagraxofusp + Azacitidine + Venetoclax — What You Need to Know
Что такое бластная плазмоцитоидная дендритноклеточная неоплазия (БПДНК) с доктором Казилбашем
Что такое бластная плазмоцитоидная дендритноклеточная неоплазия (БПДНК) с доктором Казилбашем
Improving outcomes for patients with BPDCN: alloSCT and maintenance therapy
Improving outcomes for patients with BPDCN: alloSCT and maintenance therapy
Sarah Montgomery raising awareness of BPDCN through The Jimmy Fund event
Sarah Montgomery raising awareness of BPDCN through The Jimmy Fund event
A Phase II protocol for a safe combination of chemotherapy for patients with BPDCN
A Phase II protocol for a safe combination of chemotherapy for patients with BPDCN
Anti-tumor activity and hematopoietic restoration achieved with tagraxofusp in treatment-naïve BPDCN
Anti-tumor activity and hematopoietic restoration achieved with tagraxofusp in treatment-naïve BPDCN
Genetic Characteristics of BPDCN: A Single-Institution Study | Oncotarget
Genetic Characteristics of BPDCN: A Single-Institution Study | Oncotarget
TAG in BPDCN: Dr. Anthony Stein Shares Phase 1/2 Insights
TAG in BPDCN: Dr. Anthony Stein Shares Phase 1/2 Insights
Is Frontline TAG a Safer Bridge to Transplant in BPDCN?
Is Frontline TAG a Safer Bridge to Transplant in BPDCN?
Promising approaches being explored in BPDCN: targeting CD123, BCL2, combination therapies & more
Promising approaches being explored in BPDCN: targeting CD123, BCL2, combination therapies & more
BPDCN - Blastische plasmazytoide dendritische Zellneoplasie | CME-Fortbildung | Official Trailer
BPDCN - Blastische plasmazytoide dendritische Zellneoplasie | CME-Fortbildung | Official Trailer
Efficacy and safety of pivekimab sunirine in patients with BPDCN: CADENZA study update
Efficacy and safety of pivekimab sunirine in patients with BPDCN: CADENZA study update
Long-term safety and efficacy of tagraxofusp in BPDCN: results from a subgroup analysis
Long-term safety and efficacy of tagraxofusp in BPDCN: results from a subgroup analysis
Ongoing research and unmet needs in BPDCN
Ongoing research and unmet needs in BPDCN
Investigational Treatment Strategies for BPDCN - 2025 Blood Cancer Video Library
Investigational Treatment Strategies for BPDCN - 2025 Blood Cancer Video Library
BPDCN Treatment: Tagraxofusp - 2025 Blood Cancer Video Library
BPDCN Treatment: Tagraxofusp - 2025 Blood Cancer Video Library
Treatment Overview and Recent Advances in BPDCN - 2025 Blood Cancer Video Library
Treatment Overview and Recent Advances in BPDCN - 2025 Blood Cancer Video Library
Clinical Presentation and Diagnosis of BPDCN - 2025 Blood Cancer Video Library
Clinical Presentation and Diagnosis of BPDCN - 2025 Blood Cancer Video Library
Epidemiology of Blastic Plasmacytoid Dendritic Cell Neoplasm - 2025 Blood Cancer Video Library
Epidemiology of Blastic Plasmacytoid Dendritic Cell Neoplasm - 2025 Blood Cancer Video Library
Treatment results of the tagraxofusp cohort of the BPDCN international registry
Treatment results of the tagraxofusp cohort of the BPDCN international registry
CPE Webinar: Advancing Understanding on BPDCN - Empowering Patients Through Knowledge
CPE Webinar: Advancing Understanding on BPDCN - Empowering Patients Through Knowledge
Tagraxofusp demonstrates anti-tumor activity without myelosuppression in patients with BPDCN
Tagraxofusp demonstrates anti-tumor activity without myelosuppression in patients with BPDCN